Reply To: Traders Market Weekly: A Wonderful Life for Central Bankers


Pfizer (PFE) confirms that the U.S. FDA’s Vaccines and Related Biological Products Advisory Committee voted that available data is adequate to support the safety and effectiveness of its respiratory syncytial virus bivalent vaccine candidate PF-06928316 or RSVpreF

PFE up 0.2%